BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33863674)

  • 1. Control of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Cancer.
    Karpukhina A; Tiukacheva E; Dib C; Vassetzky YS
    Trends Mol Med; 2021 Jun; 27(6):588-601. PubMed ID: 33863674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
    Gatica LV; Rosa AL
    Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.
    Hamel J; Tawil R
    Neurotherapeutics; 2018 Oct; 15(4):863-871. PubMed ID: 30361930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of
    Duranti E; Villa C
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions.
    Statland JM; Tawil R
    Curr Opin Neurol; 2011 Oct; 24(5):423-8. PubMed ID: 21734574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy.
    Jagannathan S
    Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166367. PubMed ID: 35158020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy.
    Himeda CL; Jones PL
    Annu Rev Genomics Hum Genet; 2019 Aug; 20():265-291. PubMed ID: 31018108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
    Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
    Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DICER/AGO-dependent epigenetic silencing of D4Z4 repeats enhanced by exogenous siRNA suggests mechanisms and therapies for FSHD.
    Lim JW; Snider L; Yao Z; Tawil R; Van Der Maarel SM; Rigo F; Bennett CF; Filippova GN; Tapscott SJ
    Hum Mol Genet; 2015 Sep; 24(17):4817-28. PubMed ID: 26041815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and epigenetic characteristics of FSHD-associated 4q and 10q D4Z4 that are distinct from non-4q/10q D4Z4 homologs.
    Zeng W; Chen YY; Newkirk DA; Wu B; Balog J; Kong X; Ball AR; Zanotti S; Tawil R; Hashimoto N; Mortazavi A; van der Maarel SM; Yokomori K
    Hum Mutat; 2014 Aug; 35(8):998-1010. PubMed ID: 24838473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.
    Haynes P; Bomsztyk K; Miller DG
    Epigenetics Chromatin; 2018 Aug; 11(1):47. PubMed ID: 30122154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facioscapulohumeral Muscular Dystrophy.
    DeSimone AM; Pakula A; Lek A; Emerson CP
    Compr Physiol; 2017 Sep; 7(4):1229-1279. PubMed ID: 28915324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7.
    Banerji CRS; Zammit PS
    EMBO Mol Med; 2021 Aug; 13(8):e13695. PubMed ID: 34151531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy.
    Mocciaro E; Runfola V; Ghezzi P; Pannese M; Gabellini D
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD.
    Krom YD; Thijssen PE; Young JM; den Hamer B; Balog J; Yao Z; Maves L; Snider L; Knopp P; Zammit PS; Rijkers T; van Engelen BG; Padberg GW; Frants RR; Tawil R; Tapscott SJ; van der Maarel SM
    PLoS Genet; 2013 Apr; 9(4):e1003415. PubMed ID: 23593020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene.
    Snider L; Geng LN; Lemmers RJ; Kyba M; Ware CB; Nelson AM; Tawil R; Filippova GN; van der Maarel SM; Tapscott SJ; Miller DG
    PLoS Genet; 2010 Oct; 6(10):e1001181. PubMed ID: 21060811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy.
    Himeda CL; Jones TI; Jones PL
    Mol Ther; 2016 Mar; 24(3):527-35. PubMed ID: 26527377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
    Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
    Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct interplay between two candidate genes in FSHD muscular dystrophy.
    Ferri G; Huichalaf CH; Caccia R; Gabellini D
    Hum Mol Genet; 2015 Mar; 24(5):1256-66. PubMed ID: 25326393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of epigenetic silencing of the DUX4 transcription factor gene in facioscapulohumeral muscular dystrophy.
    Hewitt JE
    Hum Mol Genet; 2015 Oct; 24(R1):R17-23. PubMed ID: 26113644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.